{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T20:14:20Z","timestamp":1648757660988},"reference-count":26,"publisher":"Elsevier BV","issue":"2","content-domain":{"domain":["trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.transci.2013.07.012","type":"journal-article","created":{"date-parts":[[2013,8,15]],"date-time":"2013-08-15T16:34:04Z","timestamp":1376584444000},"page":"116-119","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The impact of molecular biology techniques on the management of newly diagnosed chronic myeloid leukemia patients in chronic phase. A review"],"prefix":"10.1016","volume":"49","author":[{"given":"Philippe","family":"Lewalle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Martiat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2013.07.012_b0005","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00277-005-1039-z","article-title":"Chronic myeloid leukemia: a model for oncology","volume":"84","author":"Hehlmann","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.transci.2013.07.012_b0010","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.transci.2013.07.012_b0015","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2013.07.012_b0020","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2013.07.012_b0025","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.transci.2013.07.012_b0030","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.transci.2013.07.012_b0035","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2013.07.012_b0040","doi-asserted-by":"crossref","unstructured":"O\u2019Brien SG, Guilhot F, Goldman DM, et al. International Randomized Study of Interferon Versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib. Blood 2008;112. Abstract 186.","DOI":"10.1182\/blood.V112.11.186.186"},{"key":"10.1016\/j.transci.2013.07.012_b0045","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.transci.2013.07.012_b0050","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","article-title":"Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS study","volume":"21","author":"Hahn","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2013.07.012_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta8280","article-title":"Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis","volume":"8","author":"Dalziel","year":"2004","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.transci.2013.07.012_b0060","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2165\/00024669-200302060-00005","article-title":"Imatinib mesylate: a review of its use in chronic myeloid leukemia","volume":"2","author":"Curran","year":"2003","journal-title":"Am J Cancer"},{"key":"10.1016\/j.transci.2013.07.012_b0065","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1592\/phco.25.3.325.61593","article-title":"Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach","volume":"25","author":"Skrepnek","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.transci.2013.07.012_b0070","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2165\/00019053-200523050-00010","article-title":"Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia","volume":"23","author":"Dalziel","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.transci.2013.07.012_b0075","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1002\/cncr.20694","article-title":"Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia","volume":"101","author":"Reed","year":"2004","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.transci.2013.07.012_b0080","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.transci.2013.07.012_b0085","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.transci.2013.07.012_b0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.blre.2005.01.008","article-title":"Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia","volume":"20","author":"Hughes","year":"2006","journal-title":"Blood Rev"},{"issue":"5","key":"10.1016\/j.transci.2013.07.012_b0095","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.transci.2013.07.012_b0100","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.transci.2013.07.012_b0105","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.seminoncol.2011.11.002","article-title":"Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression","volume":"39","author":"Ernst","year":"2012","journal-title":"Semin Oncol"},{"issue":"22","key":"10.1016\/j.transci.2013.07.012_b0110","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.transci.2013.07.012_b0115","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ajh.23180","article-title":"Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia","volume":"87","author":"Jabbour","year":"2012","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.transci.2013.07.012_b0120","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.transci.2013.07.012_b0125","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecularand cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.transci.2013.07.012_b0130","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Intergroupe Fran\u00e7ais des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050213002395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050213002395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T00:40:30Z","timestamp":1596328830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050213002395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S1473050213002395"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2013.07.012","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of molecular biology techniques on the management of newly diagnosed chronic myeloid leukemia patients in chronic phase. A review","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2013.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}